Treatments and outcomes of peritoneal surface tumors through a centralized national service (United Kingdom)

Diseases of the Colon and Rectum

Volumn 52, Issue 10, 2009, Pages 1705-1714

  Rout, S ^a   Renehan, A G ^a,b   Parkinson, M F ^a   Saunders, M P ^a   Fulford, P E ^a   Wilson, M S ^a   O'Dwyer, S T ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Heated intraperitoneal chemotherapy; Peritoneal surface tumor; Pseudomyxoma peritonei; Sugarbaker procedure

Indexed keywords

CISPLATIN; DOXORUBICIN; MITOMYCIN C;

ADOLESCENT; ADULT; AGED; APPENDIX TUMOR; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; COLORECTAL TUMOR; CYTOREDUCTIVE SURGERY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL HEALTH SERVICE; PERITONEUM MESOTHELIOMA; PERITONEUM PSEUDOMYXOMA; PERITONEUM TUMOR; PROGNOSIS; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; GREAT BRITAIN; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PSEUDOMYXOMA PERITONEI; REFERRAL AND CONSULTATION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70350120714     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e3181b5504e     Document Type: Article

References (41)

1. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69-76.
2. Renehan AG, O' Dwyer ST, Stern PL. Pseudomyxoma peritonei. In: Schwab M, ed. Encyclopedia of cancer. London: Springer, 2009:2134-2138
3. Moran BJ. Establishment of a peritoneal malignancy treatment centre in the United Kingdom. Eur J Surg Oncol 2006;32:614-618
4. Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum 2007;50:37-42.
5. Bradley RF, Cortina G, Geisinger KR. Pseudomyxoma peritonei: review of the controversy. Curr Diagn Pathol 2007;13:410-416
6. Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003;27:1089-1103
7. Sugarbaker PH. Evolving strategies for surgical management of carcinomatosis. ANZ J Surg 2006;76:162-169
8. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res 2007;134:247-264
9. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727-731
10. 5th International Workshop on Peritoneal Surface Malignancy, Milan, Italy, December 4 to 6, 2006. Available at: http://www.peritonealworkshop2006. com. Accessed August 9, 2008.
11. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005;2:3-10.
12. de Bree E, Witkamp AJ, Zoetmulder FA. Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol 2002;79:46-61.
13. Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007; 14:41-49
14. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790-796
15. Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 2008;99:591-596
16. Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 2006;95:131-138
17. Geerts W, Ray JG, Colwell CW, et al. Prevention of venous thromboembolism. Chest 2005;128:3775-3776
18. Common terminology criteria for adverse events, version 3.0. Bethesda, MD: National Cancer Institute, 2006. Available at: http://safetyprofiler-ctep. nci.nih.gov/CTC/CTC.aspx. Accessed April 27, 2008.
19. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:813-817
20. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92:85-91.
21. World Health Organization Classification of Tumours. Pathology and genetics: tumours of the digestive system. Lyon: IARC Press, 2000.
22. Hosmer DW, Lemeshow S, May S. Applied survival analysis: regression modeling of time to event data. New York: Wiley, 2008.
23. Bradley RF, Stewart JH, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30: 551-559
24. Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 2007;94:1408-1414
25. Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004;11:393-398
26. Sugarbaker PH, Alderman R, Edwards G, Marquardt CE, Gushchin V, Esquivel J, Chang D. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 2006;13: 635-644
27. Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei-a report of 103 procedures. Eur J Surg Oncol 2006;32:186-190
28. Piso P, Bektas H, Werner U, et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 2001;27:286-290
29. Zoetmulder FA, van der Vange N, Witkamp AJ, Kaag MM, Boot H, Beijnen JH. Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute [in Dutch]. Ned Tijdschr Geneeskd 1999;143:1863-1868.
30. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004;240:278-285
31. Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg 2006;93:1270-1276
32. Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2007;14:484-492 (Pubitemid 46175292)
33. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000;66:561-568
34. Ronnett BM, Shmookler BM, Sugarbaker PH, Kurman RJ. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 1997;2: 197-226.
35. Butterworth SA, Panton ON, Klaassen DJ, Shah AM, McGregor GI. Morbidity and mortality associated with intraperitoneal chemotherapy for pseudomyxoma peritonei. Am J Surg 2002; 183:529-532
36. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007;14:2702-2713
37. Senior K. Intraperitoneal treatment lengthens survival in ovarian cancer. Lancet Oncol 2006;7:107.
38. Gilly FN. Phase II studies: international registry of colorectal carcinomatosis. Eur J Surg Oncol 2006;32:648-654
39. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007;14:128-133
40. National Institute for Health and Clinical Excellence (NICE). Complete cytoreduction and heated intraperitoneal intraoperative chemotherapy (Sugarbaker technique) for peritoneal carcinomatosis. London: National Institute for Health and Clinical Excellence, 2005. Available at: http://www.nice.org.uk/guidance/ index.jsp?action-byID&o-11152. Accessed April 27, 2008.
41. Bibi R, Pranesh N, Saunders MP, et al. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer 2006;95: 1258-1264